CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
Provided By GlobeNewswire
Last update: May 12, 2025
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) -
Read more at globenewswire.com3.45
+0.08 (+2.37%)
Find more stocks in the Stock Screener
CTMX Latest News and Analysis
